Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
18 déc. 2023 09h00 HE
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
University of Pittsburgh Automates 83% of Salesforce Testing with CAI Neurodiverse Solutions
18 oct. 2023 09h00 HE
|
CAI
University of Pittsburgh is experiencing IT department success with CAI's neurodiversity employment program, CAI Neurodiverse Solutions.
Steven J. Durning, MD, PhD, Selected as NBME’s 2022 John P. Hubbard Award Recipient
06 avr. 2022 14h32 HE
|
NBME
Philadelphia, PA, April 06, 2022 (GLOBE NEWSWIRE) -- NBME congratulates Steven J. Durning, MD, PhD, as the recipient of its 2022 John P. Hubbard Award in recognition of his extensive contributions...
Owkin and The University of Pittsburgh Launch a Collaboration to Advance Cancer Research with Artificial Intelligence and Federated Learning
05 mars 2020 08h00 HE
|
Owkin
NEW YORK and PITTSBURGH, March 05, 2020 (GLOBE NEWSWIRE) -- Owkin, a startup that deploys AI and Federated Learning technologies to augment medical research and enable scientific discoveries,...
American Health Council Names Doris M. Rubio, PhD to Education Board
28 juin 2017 08h00 HE
|
American Health Council
NEW YORK, June 28, 2017 (GLOBE NEWSWIRE) -- Dr. Doris M. Rubio, Professor of Medicine, Biostatistics, Nursing, and Clinical and Translational Science at the University of Pittsburgh, has been...
University of Pittsburgh Licenses Novel Microneedle Patch to Pittsburgh Company
03 août 2016 10h02 HE
|
SkinJect
PITTSBURGH, Aug. 03, 2016 (GLOBE NEWSWIRE) -- SkinJect, Inc., a Pittsburgh-based company, today announced its completion of a license with the University of Pittsburgh to its novel, minimally...
Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
14 juil. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced a strategic alliance to develop multiple projects with Bioclones...